|Clinical Trial Title||Olanzapine with or without fosaprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial.|
|Trial Status||Closed to Enrollment|
|Location||Doctors & Locations|
|Trial Type||Cancer - Adult Oncology|
This randomized phase III trial studies how well olanzapine with or without fosaprepitant work in preventing chemotherapy induced nausea and vomiting in cancer patients receiving chemotherapy that causes vomiting. Olanzapine and fosaprepitant dimeglumine may help control nausea and vomiting in patients during chemotherapy. Olanzapine is usually given in combination with other drugs, including fosaprepitant dimeglumine. It is not yet known if olanzapine when given with other drugs, is still effective without using fosaprepitant dimeglumine for controlling nausea and vomiting.
Please contact Legacy Oncology Research for additional study inclusion/exclusion information.
|IRB Number||Central IRB|
|Principal Investigator||Regan Look, MD|
|Contact Name||Oncology Clinical Research|